Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail
Digital
- Autores:
-
Dagenais, Gilles R.
Rydén, Lars
Leiter, Lawrence A.
Lakshmanan, Mark
Dyal, Leanne
Probstfield, Jeffrey L.
Atisso, Charles Messan
Shaw, Jonathan E.
Conget, Ignacio
Cushman, William C.
Lopez-Jaramillo, Patricio
Lanas, Fernando
Cordona Munoz, Ernesto German
Pirags, Valdis
Pogosova, Nana
Basile, Jan
Sheu, Wayne H. H.
Temelkova-Kurktschiev, Theodora
Raubenheimer, Peter J.
Keltai, Matyas
Hall, Stephanie
Pais, Prem
Colhoun, Helen M.
Riddle, Matthew C.
Gerstein, Hertzel C.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6024
- Acceso en línea:
- https://doi.org/10.1186/s12933-020-01179-1
https://repositorio.udes.edu.co/handle/001/6024
- Palabra clave:
- Rights
- openAccess
- License
- Copyrights, The Authors, BMC, 2020
| id |
RUDES2_57a3b256de4ab3b1aa0ed156bd1f723a |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/6024 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| dc.title.alternative.spa.fl_str_mv |
A post hoc analysis |
| title |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| spellingShingle |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| title_short |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| title_full |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| title_fullStr |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| title_full_unstemmed |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| title_sort |
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail |
| dc.creator.fl_str_mv |
Dagenais, Gilles R. Rydén, Lars Leiter, Lawrence A. Lakshmanan, Mark Dyal, Leanne Probstfield, Jeffrey L. Atisso, Charles Messan Shaw, Jonathan E. Conget, Ignacio Cushman, William C. Lopez-Jaramillo, Patricio Lanas, Fernando Cordona Munoz, Ernesto German Pirags, Valdis Pogosova, Nana Basile, Jan Sheu, Wayne H. H. Temelkova-Kurktschiev, Theodora Raubenheimer, Peter J. Keltai, Matyas Hall, Stephanie Pais, Prem Colhoun, Helen M. Riddle, Matthew C. Gerstein, Hertzel C. |
| dc.contributor.author.none.fl_str_mv |
Dagenais, Gilles R. Rydén, Lars Leiter, Lawrence A. Lakshmanan, Mark Dyal, Leanne Probstfield, Jeffrey L. Atisso, Charles Messan Shaw, Jonathan E. Conget, Ignacio Cushman, William C. Lopez-Jaramillo, Patricio Lanas, Fernando Cordona Munoz, Ernesto German Pirags, Valdis Pogosova, Nana Basile, Jan Sheu, Wayne H. H. Temelkova-Kurktschiev, Theodora Raubenheimer, Peter J. Keltai, Matyas Hall, Stephanie Pais, Prem Colhoun, Helen M. Riddle, Matthew C. Gerstein, Hertzel C. |
| dc.contributor.researchgroup.spa.fl_str_mv |
Everest |
| description |
Digital |
| publishDate |
2020 |
| dc.date.issued.none.fl_str_mv |
2020-11-01 |
| dc.date.accessioned.none.fl_str_mv |
2022-02-16T19:47:13Z |
| dc.date.available.none.fl_str_mv |
2022-02-16T19:47:13Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1186/s12933-020-01179-1 |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6024 |
| url |
https://doi.org/10.1186/s12933-020-01179-1 https://repositorio.udes.edu.co/handle/001/6024 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
8 |
| dc.relation.citationstartpage.spa.fl_str_mv |
1 |
| dc.relation.citationvolume.spa.fl_str_mv |
19 |
| dc.relation.cites.none.fl_str_mv |
Dagenais, G.R., Rydén, L., Leiter, L.A. et al. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol 19, 199 (2020). https://doi.org/10.1186/s12933-020-01179-1 |
| dc.relation.indexed.spa.fl_str_mv |
Scopus |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Cardiovascular Diabetology |
| dc.rights.spa.fl_str_mv |
Copyrights, The Authors, BMC, 2020 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Copyrights, The Authors, BMC, 2020 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
8 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Cardiovascular Diabetology |
| dc.publisher.place.spa.fl_str_mv |
Reino Unido |
| dc.source.spa.fl_str_mv |
https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01179-1 |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/bd0a445b-8c71-4dfd-ab97-948dd4fe9b73/download https://repositorio.udes.edu.co/bitstreams/d87f14b8-25a9-4623-8267-3210d990fcee/download https://repositorio.udes.edu.co/bitstreams/0cd1f9d1-392e-4d59-80ca-b33cf116dd42/download https://repositorio.udes.edu.co/bitstreams/8a432d70-9182-47ef-b7fa-eba5ff1e627e/download |
| bitstream.checksum.fl_str_mv |
48009a23907987b2766ec85d7c2e1b65 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 a2f1a55e26625c899332446983660cc5 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1808490903764992000 |
| spelling |
Dagenais, Gilles R.f72492d7-dc96-43b0-9237-b00656585504-1Rydén, Larsfbe7a352-5488-4e8a-866d-b966ed6789b4-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lakshmanan, Marke4d26b36-1c41-49d9-9c19-d57fb2109f53-1Dyal, Leanne2c1519ed-7131-4c64-ae64-60293a636b7c-1Probstfield, Jeffrey L.43e40b81-2244-40bf-b65c-c7ca19fe9248-1Atisso, Charles Messan74e263ba-be50-4718-b67a-32270a7c5258-1Shaw, Jonathan E.bee14056-7326-4051-b756-4d809e9c79f8-1Conget, Ignacioc0327a53-3097-438b-9a40-d441f3c20758-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Cordona Munoz, Ernesto German87a11c23-64f0-485e-923c-eeef6bd18198-1Pirags, Valdisc43a25fe-51ee-4b71-863e-54b03868e125-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Basile, Jan31df2eea-b661-4757-98a0-111336270810-1Sheu, Wayne H. H.a2436758-4d4a-4c6f-9759-0c03ccab64e4-1Temelkova-Kurktschiev, Theodoraa08e998d-95f2-4139-ae16-bd8009965b60-1Raubenheimer, Peter J.260f749c-e594-4273-a34d-e926010f883c-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Hall, Stephanie76425501-41fc-4b68-bd22-1a38e1e3d160-1Pais, Prem5abdbf77-3c3f-4396-8634-83723aa215b9-1Colhoun, Helen M.41617f18-e528-4e15-819a-0a30d7feb185-1Riddle, Matthew C.d5c956b6-8f40-43ca-83bc-4b130c672a99-1Gerstein, Hertzel C.8dbb4c88-f0dd-45f2-8bc4-590f0a1e3c3c-1Everest2022-02-16T19:47:13Z2022-02-16T19:47:13Z2020-11-01DigitalBackground The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agonist, versus matched placebo reduced the first outcome of major adverse cardiovascular event (MACE), cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (594 versus 663 events) in 9901 persons with type 2 diabetes and either chronic cardiovascular disease or risk factors, and followed during 5.4 years. These findings were based on a time-to-first-event analysis and preclude relevant information on the burden of total major events occurring during the trial. This analysis reports on the total cardiovascular or fatal events in the REWIND participants Methods We compared the total incidence of MACE or non-cardiovascular deaths, and the total incidence of expanded MACE (MACE, unstable angina, heart failure or revascularization) or non-cardiovascular deaths between participants randomized to dulaglutide and those randomized to placebo. Incidences were expressed as number per 1000 person-years. Hazard ratios (HR) were calculated using the conditional time gap and proportional means models. Results Participants had a mean age of 66.2 years, 46.3% were women and 31% had previous cardiovascular disease. During the trial there were 1972 MACE or non-cardiovascular deaths and 3673 expanded MACE or non-cardiovascular deaths. The incidence of total MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 35.8 and 40.3 per 1000 person-years, respectively [absolute reduction = 4.5 per 1000 person-years; conditional time gap HR 0.90 (95% CI, 0.82–0.98) p = 0.020, and proportional means HR 0.89 (95% CI, 0.80–0.98) p = 0.022]. The incidence of total expanded MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 67.1 and 74.7 per 1000 person-years, respectively [absolute reduction = 7.6 per 1000 person-years; conditional time gap HR 0.93 (95% CI, 0.87–0.99) p = 0.023, and proportional means HR 0.90 (95% CI, 0.82–0.99) p = 0.028]. Conclusions These findings suggest that weekly subcutaneous dulaglutide reduced total cardiovascular or fatal event burden in people with type 2 diabetes at moderate cardiovascular risk.Ciencias Médicas y de la Salud8 papplication/pdfhttps://doi.org/10.1186/s12933-020-01179-1https://repositorio.udes.edu.co/handle/001/6024engCardiovascular DiabetologyReino Unido8119Dagenais, G.R., Rydén, L., Leiter, L.A. et al. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol 19, 199 (2020). https://doi.org/10.1186/s12933-020-01179-1ScopusCardiovascular DiabetologyCopyrights, The Authors, BMC, 2020info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01179-1Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trailA post hoc analysisArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail. A post hoc analysis.pdfTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail. A post hoc analysis.pdfapplication/pdf242885https://repositorio.udes.edu.co/bitstreams/bd0a445b-8c71-4dfd-ab97-948dd4fe9b73/download48009a23907987b2766ec85d7c2e1b65MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/d87f14b8-25a9-4623-8267-3210d990fcee/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail. A post hoc analysis.pdf.txtTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail. A post hoc analysis.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/0cd1f9d1-392e-4d59-80ca-b33cf116dd42/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail. A post hoc analysis.pdf.jpgTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail. A post hoc analysis.pdf.jpgGenerated Thumbnailimage/jpeg12342https://repositorio.udes.edu.co/bitstreams/8a432d70-9182-47ef-b7fa-eba5ff1e627e/downloada2f1a55e26625c899332446983660cc5MD54001/6024oai:repositorio.udes.edu.co:001/60242023-10-10 10:19:01.386https://creativecommons.org/licenses/by-nc/4.0/Copyrights, The Authors, BMC, 2020https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |